GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » Quick Ratio

Nexien BioPharma (Nexien BioPharma) Quick Ratio : 0.01 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Nexien BioPharma Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Nexien BioPharma's quick ratio for the quarter that ended in Dec. 2023 was 0.01.

Nexien BioPharma has a quick ratio of 0.01. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Nexien BioPharma's Quick Ratio or its related term are showing as below:

NXEN' s Quick Ratio Range Over the Past 10 Years
Min: 0.01   Med: 1.31   Max: 37.63
Current: 0.01

During the past 7 years, Nexien BioPharma's highest Quick Ratio was 37.63. The lowest was 0.01. And the median was 1.31.

NXEN's Quick Ratio is ranked worse than
99.44% of 1071 companies
in the Drug Manufacturers industry
Industry Median: 1.33 vs NXEN: 0.01

Nexien BioPharma Quick Ratio Historical Data

The historical data trend for Nexien BioPharma's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexien BioPharma Quick Ratio Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Quick Ratio
Get a 7-Day Free Trial 6.91 0.79 0.67 0.52 0.15

Nexien BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.20 0.15 0.07 0.01

Competitive Comparison of Nexien BioPharma's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexien BioPharma's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Nexien BioPharma's Quick Ratio falls into.



Nexien BioPharma Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Nexien BioPharma's Quick Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Quick Ratio (A: Jun. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.043-0)/0.295
=0.15

Nexien BioPharma's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.003-0)/0.317
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nexien BioPharma  (OTCPK:NXEN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Nexien BioPharma Quick Ratio Related Terms

Thank you for viewing the detailed overview of Nexien BioPharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexien BioPharma (Nexien BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is a researcher and developer of cannabinoid-based pharmaceutical for various medical conditions and disorders, all under U.S. Food and Drug Administration development pathways.
Executives
Jeffrey Friedland other: Former 10% Owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Usa Inc. 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Inc. 10 percent owner 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246
Joseph F Aceto officer: VP Legal & IP Counsel 1617 NEWARK ROAD, KENNETT SQUARE PA 19348
Jeremy Robert Reeh officer: VP Translational Research 11 TANKARD LANE, WASHINGTON CROSSING PA 18977
Alexander Michael Wasyl director, officer: Chief Executive Officer 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977
Frank J Manganella officer: VP Corporate Development 148-26 10TH AVENUE, WHITESTONE NY 11357
Clark Courtney Lynne director PO BOX 7801, ASPEN CO 81612
Lindy Snider director 408 BARBARA LANE, BRYN MAWR PA 19010
Robert I Goldfarb officer: Chief Operating Officer 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160
Evan L Wasoff officer: Chief Financial Officer 101 WINGER DRIVE, NEDERLAND CO 80466
Alain D Bankier director 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023
Richard S Greenberg director, 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Ivo Heiden director, 10 percent owner 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108